BusinessSummit Enters Into Licence and Commercialisation Agreement With Eurofarma for Latin American Rights to Ridinilazole, Summit’s Precision Antibiotic in Development for the Treatment of CDIBy Nasdaq OMXDec 21, 2017, 7:00 AM UTC
BusinessAssembly Biosciences Announces the Closing and Early Termination of Hart-Scott-Rodino Waiting Period for License of Microbiome Gastrointestinal Development Programs to AllerganBy Nasdaq OMXFeb 21, 2017, 12:05 PM UTC
BusinessAllergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development ProgramsBy Nasdaq OMXJan 9, 2017, 1:02 PM UTC
BusinessAllergan Enters Into Licensing Agreement with Assembly Biosciences to Obtain Worldwide Rights to Microbiome Gastrointestinal Development ProgramsBy Nasdaq OMXJan 9, 2017, 1:02 PM UTC
